1. Home
  2. ECF vs GNLX Comparison

ECF vs GNLX Comparison

Compare ECF & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ellsworth Growth and Income Fund Ltd.

ECF

Ellsworth Growth and Income Fund Ltd.

HOLD

Current Price

$11.95

Market Cap

176.2M

Sector

Finance

ML Signal

HOLD

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.48

Market Cap

110.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECF
GNLX
Founded
1986
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
176.2M
110.4M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
ECF
GNLX
Price
$11.95
$2.48
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $17.25
AVG Volume (30 Days)
26.0K
★ 266.4K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
★ 6.42%
N/A
EPS Growth
N/A
★ 9.47
EPS
★ 0.46
N/A
Revenue
N/A
★ $8,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$26.13
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.71
$2.29
52 Week High
$13.85
$8.54

Technical Indicators

Market Signals
Indicator
ECF
GNLX
Relative Strength Index (RSI) 36.60 44.65
Support Level $11.24 $2.34
Resistance Level $12.68 $2.86
Average True Range (ATR) 0.20 0.14
MACD -0.02 0.01
Stochastic Oscillator 1.25 39.29

Price Performance

Historical Comparison
ECF
GNLX

About ECF Ellsworth Growth and Income Fund Ltd.

Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Share on Social Networks: